Luna Diabetes Raises $26.3M in Series A Funding

Luna Diabetes today announced it has successfully raised $26,300,000 in new investment capital. This significant funding round is set to accelerate the company’s mission to bring the incredible and life-changing benefits of automated insulin delivery to those who currently use insulin pens. The investment underscores confidence in Luna Diabetes' approach to enhancing diabetes management. The company was formed by a founding team with a strong history in the diabetes sector, having previously developed some of the most widely-used diabetes products globally. Leveraging this extensive experience, Luna Diabetes is committed to making daily life with diabetes simpler, safer, and more balanced. Their focus is on transformative design and a relentless dedication to the user, aiming to deliver "the gift of more restful sleep and magical mornings" for people living with the condition. This injection of capital marks a pivotal moment for Luna Diabetes. The funds will be strategically deployed to advance product development, scale operational capabilities, and expand market outreach. This investment is crucial as the company progresses towards making its innovative automated insulin delivery solutions more accessible to a broader population of insulin pen users, directly addressing an unmet need in the market. The successful funding round positions Luna Diabetes for sustained growth and continued innovation. The company remains focused on its vision of transforming diabetes care, working to ensure that more individuals can experience the benefits of advanced insulin management technology and ultimately achieve a better quality of life.